Accurate International
Provides a tumor organoid drug sensitivity detection platform for scientific research and clinical precision treatment.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
* | CNY100m | Series B | |
| Total Funding | 000k | ||
Related Content
Bio-Accurate is at the forefront of the organoid technology sector, focusing on advanced cancer research and personalized medicine. The company develops and utilizes organoids, which are miniaturized and simplified versions of organs, to create more accurate models for studying diseases and testing treatments. This innovative approach allows for more precise and effective drug development, ultimately leading to better patient outcomes. Bio-Accurate serves pharmaceutical companies, research institutions, and healthcare providers, operating within the biotechnology and healthcare markets. The business model is centered around providing cutting-edge organoid-based solutions and services, generating revenue through partnerships, licensing agreements, and direct sales of their proprietary technology. The recent completion of a Pre B round of financing, raising RMB 100 million, underscores the company's strong market position and growth potential. Key investors include Fortune Capital, Guangzhou Jinkong Fund, and GDD Industry Fund Investment Group, among others.
Keywords: organoid technology, cancer research, personalized medicine, biotechnology, healthcare, drug development, pharmaceutical partnerships, licensing agreements, innovative solutions, advanced treatments.